Compare Pharmaceutical Stocks

Compare Pharmaceutical stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., AMGN, GILD, REGN, VRTX) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMGN Amgen	$288.23 +1.2%	$293.23	$253.30 ▼ $339.17	$153.27B	0.49	2.05 million shs	1.80 million shs
GILD Gilead Sciences	$119.41 +8.3%	$110.93	$72.43 ▼ $121.38	$137.18B	0.33	5.81 million shs	13.11 million shs
REGN Regeneron Pharmaceuticals	$563.00 +0.6%	$536.80	$476.49 ▼ $1,211.20	$60.44B	0.33	969,491 shs	1.02 million shs
VRTX Vertex Pharmaceuticals	$366.54 -2.4%	$450.77	$364.66 ▼ $519.88	$96.31B	0.44	1.99 million shs	3.68 million shs
ABBV AbbVie	$198.10 -0.4%	$189.65	$163.81 ▼ $218.66	$351.30B	0.5	5.21 million shs	4.10 million shs
BMY Bristol Myers Squibb	$45.96 +1.3%	$47.32	$42.96 ▼ $63.33	$92.33B	0.36	13.75 million shs	9.99 million shs
JNJ Johnson & Johnson	$173.40 +1.1%	$159.26	$140.68 ▼ $173.96	$413.10B	0.41	9.50 million shs	7.69 million shs
LLY Eli Lilly and Company	$625.15 -2.5%	$774.10	$623.78 ▼ $972.53	$607.37B	0.44	4.83 million shs	14.09 million shs
MRK Merck & Co., Inc.	$80.73 +0.4%	$80.74	$73.31 ▼ $120.30	$200.75B	0.38	12.39 million shs	6.88 million shs
PFE Pfizer	$24.57 +1.4%	$24.44	$20.92 ▼ $30.43	$137.76B	0.52	46.49 million shs	36.36 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMGN Amgen	+1.24%	-2.91%	-2.80%	+8.41%	-7.77%
GILD Gilead Sciences	+8.28%	+5.50%	+5.45%	+23.28%	+61.36%
REGN Regeneron Pharmaceuticals	+0.57%	+0.74%	+1.89%	+6.67%	-47.27%
VRTX Vertex Pharmaceuticals	-2.42%	-20.68%	-23.47%	-13.82%	-21.32%
ABBV AbbVie	-0.34%	+1.50%	+3.86%	+7.49%	+5.64%
BMY Bristol Myers Squibb	+1.42%	+3.86%	-3.61%	-0.91%	-1.14%
JNJ Johnson & Johnson	+1.16%	+3.63%	+11.10%	+12.61%	+9.13%
LLY Eli Lilly and Company	-2.35%	-17.90%	-20.57%	-15.09%	-19.04%
MRK Merck & Co., Inc.	+0.55%	+1.84%	-3.59%	+6.39%	-28.23%
PFE Pfizer	+1.34%	+4.60%	-3.87%	+10.28%	-14.81%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALNY Alnylam Pharmaceuticals	3.8971 of 5 stars	2.4	3.0	0.0	4.3	3.2	2.5	0.6
AMGN Amgen	4.5751 of 5 stars	2.2	3.0	3.3	3.9	3.4	2.5	1.9
ARGX argenex	4.1058 of 5 stars	3.6	4.0	0.0	0.0	2.8	1.7	3.1
AZN AstraZeneca	2.8574 of 5 stars	2.4	5.0	1.7	0.0	3.0	0.0	1.3
BGNE BeiGene	1.6326 of 5 stars	3.5	0.0	0.0	0.0	1.1	0.8	0.6
BIIB Biogen	4.9104 of 5 stars	4.2	4.0	0.0	3.7	3.2	2.5	2.5
BMRN BioMarin Pharmaceutical	4.9933 of 5 stars	4.4	5.0	0.0	3.3	3.9	2.5	4.4
BNTX BioNTech	1.9531 of 5 stars	3.4	3.0	0.0	0.0	2.4	0.8	0.0
GILD Gilead Sciences	4.6521 of 5 stars	1.4	3.0	4.2	4.1	2.9	2.5	3.1
GMAB Genmab A/S	3.6739 of 5 stars	3.3	3.0	0.0	0.0	3.8	0.0	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMGN Amgen	2.33	Hold	$303.76	5.39% Upside
GILD Gilead Sciences	2.80	Moderate Buy	$114.82	-3.85% Downside
REGN Regeneron Pharmaceuticals	2.75	Moderate Buy	$832.73	47.91% Upside
VRTX Vertex Pharmaceuticals	2.56	Moderate Buy	$497.10	35.62% Upside
ABBV AbbVie	2.93	Moderate Buy	$214.43	8.24% Upside
BMY Bristol Myers Squibb	2.24	Hold	$56.38	22.66% Upside
JNJ Johnson & Johnson	2.65	Moderate Buy	$174.50	0.63% Upside
LLY Eli Lilly and Company	2.67	Moderate Buy	$984.41	57.47% Upside
MRK Merck & Co., Inc.	2.35	Hold	$107.44	33.08% Upside
PFE Pfizer	2.39	Hold	$28.12	14.44% Upside

Current Analyst Ratings Breakdown

Latest Pharmaceutical Stocks Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	GILD Gilead Sciences	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$96.00 ➝ $98.00
8/8/2025	GILD Gilead Sciences	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$108.00 ➝ $112.00
8/8/2025	GILD Gilead Sciences	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$108.00 ➝ $127.00
8/8/2025	LLY Eli Lilly and Company	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$1,050.00 ➝ $895.00
8/7/2025	ABBV AbbVie	Daiwa America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/7/2025	ABBV AbbVie	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$214.00
8/7/2025	LLY Eli Lilly and Company	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/7/2025	LLY Eli Lilly and Company	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$715.00
8/6/2025	AMGN Amgen	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$305.00 ➝ $310.00
8/6/2025	AMGN Amgen	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$330.00 ➝ $333.00
8/6/2025	AMGN Amgen	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$326.00 ➝ $317.00

(Data available from 8/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMGN Amgen	$33.42B	4.64	$30.76 per share	9.37	$13.80 per share	20.89
GILD Gilead Sciences	$28.75B	5.17	$7.44 per share	16.05	$15.44 per share	7.73
REGN Regeneron Pharmaceuticals	$14.20B	4.28	$45.96 per share	12.25	$277.30 per share	2.03
VRTX Vertex Pharmaceuticals	$11.02B	8.53	N/A	N/A	$66.99 per share	5.47
ABBV AbbVie	$56.33B	6.21	$14.87 per share	13.32	($0.08) per share	-2,476.25
BMY Bristol Myers Squibb	$48.30B	1.94	$5.97 per share	7.70	$8.59 per share	5.35
JNJ Johnson & Johnson	$88.82B	4.70	$13.27 per share	13.07	$32.58 per share	5.32
LLY Eli Lilly and Company	$45.04B	13.15	$13.89 per share	45.02	$15.03 per share	41.59
MRK Merck & Co., Inc.	$64.17B	3.14	$9.51 per share	8.49	$19.64 per share	4.11
PFE Pfizer	$63.63B	2.20	$4.43 per share	5.55	$15.66 per share	1.57

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMGN Amgen	$4.09B	$12.23	23.57	13.47	2.44	18.96%	174.71%	13.12%	N/A
GILD Gilead Sciences	$480M	$4.75	23.79	14.72	0.70	21.86%	51.45%	17.17%	N/A
REGN Regeneron Pharmaceuticals	$4.41B	$39.68	14.19	14.81	1.89	31.37%	15.06%	11.77%	N/A
VRTX Vertex Pharmaceuticals	-$535.60M	$13.99	26.20	20.93	N/A	31.86%	23.91%	17.14%	N/A
ABBV AbbVie	$4.28B	$2.10	94.33	14.17	1.28	6.45%	699.66%	13.64%	N/A
BMY Bristol Myers Squibb	-$8.95B	$2.48	18.53	7.55	2.32	10.58%	80.04%	14.69%	N/A
JNJ Johnson & Johnson	$14.07B	$9.35	18.55	15.66	2.18	25.00%	32.49%	13.00%	10/21/2025 (Estimated)
LLY Eli Lilly and Company	$10.59B	$12.29	40.86	20.09	0.91	25.91%	98.25%	17.92%	N/A
MRK Merck & Co., Inc.	$17.12B	$6.49	12.44	8.15	0.85	25.79%	41.05%	16.55%	N/A
PFE Pfizer	$8.03B	$1.88	13.07	8.11	0.87	16.84%	21.42%	9.12%	N/A

Latest Pharmaceutical Stocks Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	GILD Gilead Sciences	$1.96	$2.01	+$0.05	$1.55	$6.95 billion	$7.08 billion
8/7/2025	Q2 2025	LLY Eli Lilly and Company	$5.59	$6.31	+$0.72	$6.29	$14.40 billion	$15.56 billion
8/5/2025	Q2 2025	AMGN Amgen	$5.28	$6.02	+$0.74	$2.65	$8.86 billion	$9.18 billion
8/5/2025	Q2 2025	PFE Pfizer	$0.58	$0.78	+$0.20	$0.51	$13.43 billion	$14.65 billion
8/4/2025	Q2 2025	VRTX Vertex Pharmaceuticals	$4.24	$4.52	+$0.28	$3.99	$2.90 billion	$2.94 billion
8/1/2025	Q2 2025	REGN Regeneron Pharmaceuticals	$8.43	$12.89	+$4.46	$12.81	$3.30 billion	$3,675,600.00 billion
7/31/2025	Q2 2025	ABBV AbbVie	$3.24	$2.97	-$0.27	$0.52	$14.93 billion	$15.42 billion
7/31/2025	Q2 2025	BMY Bristol Myers Squibb	$1.07	$1.46	+$0.39	$0.64	$11.32 billion	$12.27 billion
7/29/2025	Q2 2025	MRK Merck & Co., Inc.	$2.03	$2.13	+$0.10	$1.76	$15.92 billion	$15.81 billion
7/16/2025	Q2 2025	JNJ Johnson & Johnson	$2.68	$2.77	+$0.09	$2.29	$22.85 billion	$23.74 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMGN Amgen	$9.52	3.30%	N/A	77.84%	14 Years
GILD Gilead Sciences	$3.16	2.65%	N/A	66.53%	10 Years
REGN Regeneron Pharmaceuticals	$3.52	0.63%	N/A	8.87%	N/A
VRTX Vertex Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ABBV AbbVie	$6.56	3.31%	N/A	312.38%	53 Years
BMY Bristol Myers Squibb	$2.48	5.40%	N/A	100.00%	17 Years
JNJ Johnson & Johnson	$5.20	3.00%	N/A	55.61%	64 Years
LLY Eli Lilly and Company	$6.00	0.96%	N/A	48.82%	11 Years
MRK Merck & Co., Inc.	$3.24	4.01%	N/A	49.92%	14 Years
PFE Pfizer	$1.72	7.00%	N/A	91.49%	16 Years

Latest Pharmaceutical Stocks Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/22/2025	MRK Merck & Co., Inc.	quarterly	$0.81	3.97%	9/15/2025	9/15/2025	10/7/2025
8/8/2025	GILD Gilead Sciences	quarterly	$0.79	2.7%	9/15/2025	9/15/2025	9/29/2025
8/1/2025	AMGN Amgen	quarterly	$2.38	3.21%	8/22/2025	8/22/2025	9/12/2025
6/23/2025	LLY Eli Lilly and Company	quarterly	$1.50	0.78%	8/15/2025	8/15/2025	9/10/2025
7/16/2025	JNJ Johnson & Johnson	quarterly	$1.30	3.35%	8/26/2025	8/26/2025	9/9/2025
8/8/2025	REGN Regeneron Pharmaceuticals	quarterly	$0.88	0.6%	8/18/2025	8/18/2025	9/3/2025
6/25/2025	PFE Pfizer	quarterly	$0.43	7.08%	7/25/2025	7/25/2025	9/2/2025
6/20/2025	ABBV AbbVie	quarterly	$1.64	3.54%	7/15/2025	7/15/2025	8/15/2025
6/17/2025	BMY Bristol Myers Squibb	quarterly	$0.62	5.25%	7/3/2025	7/3/2025	8/1/2025
5/27/2025	MRK Merck & Co., Inc.	quarterly	$0.81	4.18%	6/16/2025	6/16/2025	7/8/2025
5/20/2025	REGN Regeneron Pharmaceuticals	quarterly	$0.88	0.6%	5/20/2025	5/20/2025	6/6/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	4.10	2.80	2.98
AMGN Amgen	7.24	1.31	0.88
ARGX argenex	N/A	5.60	5.27
AZN AstraZeneca	0.55	0.86	0.67
BGNE BeiGene	0.05	1.93	1.72
BIIB Biogen	0.36	2.50	1.79
BMRN BioMarin Pharmaceutical	0.10	5.56	3.49
BNTX BioNTech	0.01	8.61	10.02
GILD Gilead Sciences	1.16	1.37	1.23
GMAB Genmab A/S	N/A	5.34	5.32

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMGN Amgen	76.50%
GILD Gilead Sciences	83.67%
REGN Regeneron Pharmaceuticals	83.31%
VRTX Vertex Pharmaceuticals	90.96%
ABBV AbbVie	70.23%
BMY Bristol Myers Squibb	76.41%
JNJ Johnson & Johnson	69.55%
LLY Eli Lilly and Company	82.53%
MRK Merck & Co., Inc.	76.07%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
AMGN Amgen	0.76%
GILD Gilead Sciences	0.27%
REGN Regeneron Pharmaceuticals	7.02%
VRTX Vertex Pharmaceuticals	0.20%
ABBV AbbVie	0.25%
BMY Bristol Myers Squibb	0.09%
JNJ Johnson & Johnson	0.16%
LLY Eli Lilly and Company	0.13%
MRK Merck & Co., Inc.	0.13%
PFE Pfizer	0.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMGN Amgen	28,000	538.36 million	533.62 million	Optionable
GILD Gilead Sciences	17,600	1.24 billion	1.24 billion	Optionable
REGN Regeneron Pharmaceuticals	15,106	107.96 million	100.39 million	Optionable
VRTX Vertex Pharmaceuticals	6,100	256.39 million	256.28 million	Optionable
ABBV AbbVie	55,000	1.77 billion	1.76 billion	Optionable
BMY Bristol Myers Squibb	34,100	2.04 billion	2.03 billion	Optionable
JNJ Johnson & Johnson	138,100	2.41 billion	2.40 billion	Optionable
LLY Eli Lilly and Company	47,000	947.74 million	946.50 million	Optionable
MRK Merck & Co., Inc.	75,000	2.50 billion	2.49 billion	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable

Pharmaceutical Stocks Headlines

Recent News About These Companies

Lcnb Corp Has $338,000 Position in Pfizer Inc. (NYSE:PFE)

1 hour ago | marketbeat.com

MUFG Securities EMEA plc Trims Holdings in Pfizer Inc. (NYSE:PFE)

1 hour ago | marketbeat.com

Donoghue Forlines LLC Buys Shares of 56,592 Pfizer Inc. (NYSE:PFE)

1 hour ago | marketbeat.com

Townsquare Capital LLC Has $13.93 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

1 hour ago | marketbeat.com

Leerink Partnrs Forecasts Pfizer's Q3 Earnings (NYSE:PFE)

5 hours ago | americanbankingnews.com

FDA to Review Arvinas (ARVN) and Pfizer's Breast Cancer Drug

August 8 at 5:16 PM | gurufocus.com

Goldman Sachs Sticks to Its Hold Rating for Pfizer (PFE)

August 8 at 3:48 PM | theglobeandmail.com

Pfizer (PFE) Releases Financial Results for Q2 2025

August 8 at 3:48 PM | finance.yahoo.com

FY2027 EPS Estimates for Pfizer Cut by Leerink Partnrs

August 8 at 11:44 AM | marketbeat.com

4 High-Yield Blue Chips Near 52-Week Lows: All Are Strong Buys Now

August 8 at 9:17 AM | 247wallst.com

Zions Bancorporation National Association UT Acquires Shares of 275,128 Pfizer Inc. (NYSE:PFE)

August 8 at 8:43 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Shares Acquired by Everett Harris & Co. CA

August 8 at 8:10 AM | marketbeat.com

Forsta AP Fonden Has $36.76 Million Stock Position in Pfizer Inc. (NYSE:PFE)

August 8 at 8:00 AM | marketbeat.com

Bristlecone Advisors LLC Has $5.11 Million Stock Position in Pfizer Inc. (NYSE:PFE)

August 8 at 7:22 AM | marketbeat.com

Swiss National Bank Decreases Position in Pfizer Inc. (NYSE:PFE)

August 8 at 6:48 AM | marketbeat.com

CureVac Resolves Patent Litigation with Pfizer/BioNTech

August 8 at 6:36 AM | tipranks.com

Y.D. More Investments Ltd Sells 12,907 Shares of Pfizer Inc. (NYSE:PFE)

August 8 at 6:07 AM | marketbeat.com

Maryland State Retirement & Pension System Sells 39,840 Shares of Pfizer Inc. (NYSE:PFE)

August 8 at 5:55 AM | marketbeat.com

CureVac settles patent dispute litigation with Pfizer and BioNTech

August 7 at 9:00 PM | reuters.com

Pfizer’s MAGNETISMM-6 Study: A New Horizon in Multiple Myeloma Treatment

August 7 at 12:54 PM | tipranks.com

Pfizer’s Observational Study on Multiple Myeloma: Key Insights for Investors

August 7 at 12:54 PM | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Healthcare Stocks Hit Valuation Bottom, 3 Names to Rebound
By Gabriel Osorio-Mazilli | July 23, 2025
View Healthcare Stocks Hit Valuation Bottom, 3 Names to Rebound
AbbVie Stock Eyes Breakout as Pipeline and Profits Grow
By Chris Markoch | July 31, 2025
View AbbVie Stock Eyes Breakout as Pipeline and Profits Grow
JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now
By Thomas Hughes | July 16, 2025
View JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now
Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity?
By Leo Miller | August 8, 2025
View Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity?
Are Growth Stocks Back? 3 That Look Like Winners to Buy Now
By Jeffrey Neal Johnson | July 10, 2025
View Are Growth Stocks Back? 3 That Look Like Winners to Buy Now

Pharmaceutical Stocks Company Descriptions

Amgen NASDAQ:AMGN

$288.23 +3.53 (+1.24%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$287.76 -0.47 (-0.16%)

As of 08/8/2025 07:59 PM Eastern

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Gilead Sciences NASDAQ:GILD

$119.41 +9.13 (+8.28%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$119.25 -0.16 (-0.13%)

As of 08/8/2025 07:57 PM Eastern

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Regeneron Pharmaceuticals NASDAQ:REGN

$563.00 +3.20 (+0.57%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$559.60 -3.40 (-0.60%)

As of 08/8/2025 07:48 PM Eastern

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Vertex Pharmaceuticals NASDAQ:VRTX

$366.54 -9.09 (-2.42%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$366.75 +0.21 (+0.06%)

As of 08/8/2025 07:58 PM Eastern

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

AbbVie NYSE:ABBV

$198.10 -0.76 (-0.38%)

Closing price 08/8/2025 03:59 PM Eastern

Extended Trading

$198.26 +0.16 (+0.08%)

As of 08/8/2025 07:56 PM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Bristol Myers Squibb NYSE:BMY

$45.96 +0.60 (+1.32%)

Closing price 08/8/2025 03:59 PM Eastern

Extended Trading

$45.82 -0.14 (-0.30%)

As of 08/8/2025 07:58 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Johnson & Johnson NYSE:JNJ

$173.40 +1.87 (+1.09%)

Closing price 08/8/2025 03:59 PM Eastern

Extended Trading

$172.53 -0.87 (-0.50%)

As of 08/8/2025 07:57 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Eli Lilly and Company NYSE:LLY

$625.15 -15.71 (-2.45%)

Closing price 08/8/2025 03:59 PM Eastern

Extended Trading

$625.95 +0.80 (+0.13%)

As of 08/8/2025 08:00 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Merck & Co., Inc. NYSE:MRK

$80.73 +0.36 (+0.45%)

Closing price 08/8/2025 03:59 PM Eastern

Extended Trading

$80.74 +0.02 (+0.02%)

As of 08/8/2025 07:58 PM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Pfizer NYSE:PFE

$24.57 +0.34 (+1.40%)

Closing price 08/8/2025 03:59 PM Eastern

Extended Trading

$24.56 0.00 (-0.02%)

As of 08/8/2025 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Pharmaceutical Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest Pharmaceutical Stocks Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest Pharmaceutical Stocks Earnings

Compare Dividends

Latest Pharmaceutical Stocks Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

Pharmaceutical Stocks Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

Pharmaceutical Stocks Company Descriptions

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools